Ergoteles’s Tourmaline Bio TRML Stock Holding History

Ergoteles’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,352	Closed	-$44.4K	–	1759
2022 Q4	$44.4K	Buy	+4,352	New	+$69.9K	﹤0.01%	1307

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ergoteles's TRML Position: Q1 2023 in Review

Ergoteles sold out of Tourmaline Bio (TRML) in Q1 2023, closing a stake of 4,352 shares — an estimated $44.4K sold.

Ergoteles first reported a position in TRML in Q4 2022 and held it in 1 quarter. The position peaked at $44.4K in Q4 2022. 54 funds tracked by Wall St. Rank hold TRML as of Q1 2023.

Ergoteles reported no remaining Tourmaline Bio position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 4,352 Tourmaline Bio shares in Q1 2023, an estimated $44.4K.
Ergoteles first reported a position in Tourmaline Bio in Q4 2022 and held it in 1 quarter.
Ergoteles's Tourmaline Bio position peaked at $44.4K in Q4 2022.
54 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.